debrisoquin has been researched along with Cancer of Lung in 23 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Three examples of pharmacogenetic risk factors are discussed: the first two are p450 enzymes whose activity has been associated with susceptibility to lung cancer (debrisoquine hydroxylase, aryl hydrocarbon hydroxylase), and the last, N-acetyltransferase, a non-p450 enzyme, has been associated with bladder cancer susceptibility." | 3.68 | Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens. ( Caporaso, N, 1991) |
| " Determination of debrisoquine oxidation phenotype was carried out in 119 healthy subjects, 135 patients with chronic bronchitis and 153 patients with lung cancer, all of Caucasian origin." | 3.68 | Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. ( Barre, J; Bechtel, P; Brochard, P; Dalphin, JC; de Cremoux, H; Depierre, A; Duche, JC; Joanne, C; Tillement, JP, 1991) |
| "Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502D6." | 1.28 | The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. ( Caporaso, NE; Harris, CC; Hoover, R; Landi, MT; Shaw, GL; Shields, PG; Sugimura, H; Tucker, MA; Weston, A, 1992) |
| "Debrisoquine phenotyping has potential for identifying carcinogen-exposed workers at high risk of lung cancer." | 1.28 | Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. ( Ayesh, R; Caporaso, N; Dosemeci, M; Hayes, RB; Hetzel, M; Hoover, R; Idle, J, 1989) |
| "Accordingly, two groups of cancer patients were investigated with debrisoquine, namely Nigerians with hepatocellular and related tumours and white smokers with bronchial carcinoma in the United Kingdom." | 1.26 | Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis. ( Idle, JR; Ritchie, JC, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 18 (78.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ritchie, JC | 1 |
| Idle, JR | 1 |
| Shaw, GL | 4 |
| Falk, RT | 2 |
| Deslauriers, J | 1 |
| Nesbitt, JC | 1 |
| McKneally, MF | 1 |
| Frame, JN | 2 |
| Feld, R | 1 |
| Issaq, HJ | 3 |
| Ruckdeschel, JC | 1 |
| Hoover, RN | 4 |
| Hirvonen, A | 1 |
| Husgafvel-Pursiainen, K | 1 |
| Anttila, S | 1 |
| Karjalainen, A | 1 |
| Pelkonen, O | 2 |
| Vainio, H | 1 |
| Smyth, JF | 1 |
| Christensen, PM | 1 |
| Gøtzsche, PC | 1 |
| Brøsen, K | 1 |
| Weiffenbach, B | 1 |
| Moir, DT | 1 |
| Caporaso, N | 5 |
| Caporaso, NE | 4 |
| Shields, PG | 1 |
| Landi, MT | 1 |
| Tucker, MA | 2 |
| Hoover, R | 2 |
| Sugimura, H | 2 |
| Weston, A | 3 |
| Harris, CC | 3 |
| Horsmans, Y | 1 |
| Desager, JP | 1 |
| Harvengt, C | 1 |
| Benítez, J | 1 |
| Ladero, JM | 1 |
| Jara, C | 1 |
| Carrillo, JA | 1 |
| Cobaleda, J | 1 |
| Llerena, A | 1 |
| Vargas, E | 1 |
| Muñoz, JJ | 1 |
| Duche, JC | 1 |
| Joanne, C | 1 |
| Barre, J | 1 |
| de Cremoux, H | 1 |
| Dalphin, JC | 1 |
| Depierre, A | 1 |
| Brochard, P | 1 |
| Tillement, JP | 1 |
| Bechtel, P | 1 |
| Taghizadeh, K | 1 |
| Tannenbaum, SR | 1 |
| Skipper, PL | 1 |
| Resau, JH | 3 |
| Trump, BF | 2 |
| Modali, RV | 1 |
| Gonzalez, FJ | 1 |
| Green-Gallo, LA | 1 |
| Buivys, DM | 1 |
| Fisher, KL | 1 |
| Slawson, RG | 1 |
| Elias, G | 1 |
| Didolkar, MS | 1 |
| Ivusich, WJ | 1 |
| Speirs, CJ | 1 |
| Murray, S | 1 |
| Davies, DS | 2 |
| Biola Mabadeje, AF | 1 |
| Boobis, AR | 2 |
| Law, MR | 2 |
| Hayes, RB | 2 |
| Pickle, LW | 2 |
| Muschik, GM | 1 |
| Green-Gallo, L | 1 |
| Buivys, D | 1 |
| Aisner, S | 1 |
| Dosemeci, M | 1 |
| Ayesh, R | 2 |
| Hetzel, M | 2 |
| Idle, J | 2 |
| Hetzel, MR | 1 |
| Idel, JR | 1 |
| Bale, S | 1 |
| Roots, I | 1 |
| Drakoulis, N | 1 |
| Ploch, M | 1 |
| Heinemeyer, G | 1 |
| Loddenkemper, R | 1 |
| Minks, T | 1 |
| Nitz, M | 1 |
| Otte, F | 1 |
| Koch, M | 1 |
3 reviews available for debrisoquin and Cancer of Lung
| Article | Year |
|---|---|
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Topics: Cytochrome P-450 CYP2D6; Debrisoquin; Disease Susceptibility; Genotype; Humans; Lung Neoplasms; Odds | 1997 |
Carcinogen metabolism and individual susceptibility.
Topics: Acetylation; Animals; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carcinogens; Debrisoquin; Forecasti | 1992 |
Genetic predisposition to lung cancer.
Topics: Antigens, Neoplasm; Antipyrine; Aryl Hydrocarbon Hydroxylases; Chromosome Aberrations; Chromosome Di | 1990 |
20 other studies available for debrisoquin and Cancer of Lung
| Article | Year |
|---|---|
Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
Topics: Animals; Biotransformation; Carcinoma, Bronchogenic; Debrisoquin; Humans; Isoquinolines; Lung Neopla | 1982 |
Lung tumor resection does not affect debrisoquine metabolism.
Topics: Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Debrisoquin; Female; Humans; Lung Neoplasms; M | 1994 |
PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Topics: Aged; Alleles; Base Sequence; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; | 1993 |
Cancer genetics and cell and molecular biology. Is this the way forward?
Topics: Antihypertensive Agents; Antineoplastic Agents; Debrisoquin; Extracellular Matrix; Humans; Lung Neop | 1996 |
Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.
Topics: Alleles; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP | 1997 |
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Topics: Case-Control Studies; Debrisoquin; Genotype; Humans; Lung Neoplasms; Phenotype; Polymerase Chain Rea | 1992 |
Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
Topics: Adult; Aged; Debrisoquin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxidation-Reduction; Ph | 1991 |
Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Topics: Biotransformation; Carcinogens, Environmental; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytoch | 1991 |
Polymorphic oxidation of debrisoquine in lung cancer patients.
Topics: Aged; Carcinoma, Bronchogenic; Debrisoquin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxida | 1991 |
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Bronchitis; Chronic Disease; Debrisoquin; Female; Humans; Lung Neopl | 1991 |
Measurement of 4-aminobiphenyl-hemoglobin adducts in lung cancer cases and controls.
Topics: Aminobiphenyl Compounds; Carcinogens; Case-Control Studies; Chromatography, Gas; Cotinine; Debrisoqu | 1991 |
Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cytochrome P-450 CYP2D6; Cytochrome | 1990 |
A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.
Topics: Blood Pressure; Case-Control Studies; Clinical Protocols; Debrisoquin; Humans; Lung Neoplasms; Middl | 1991 |
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Debrisoqui | 1990 |
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Topics: Debrisoquin; Disease Susceptibility; Gas Chromatography-Mass Spectrometry; Humans; Lung Neoplasms; O | 1990 |
Lung cancer and the debrisoquine metabolic phenotype.
Topics: Adenocarcinoma; Case-Control Studies; Debrisoquin; Female; Humans; Isoquinolines; Lung Diseases, Obs | 1990 |
Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
Topics: Asbestos; Debrisoquin; Female; Humans; Isoquinolines; Lung Diseases, Obstructive; Lung Neoplasms; Ma | 1989 |
Debrisoquine metabolism and genetic predisposition to lung cancer.
Topics: Debrisoquin; Disease Susceptibility; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Age | 1989 |
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Topics: Chromatography, Gas; Data Interpretation, Statistical; Debrisoquin; Gene Frequency; Genetic Predispo | 1989 |
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Topics: ABO Blood-Group System; Acetylation; Acetyltransferases; Arylamine N-Acetyltransferase; Caffeine; Ca | 1988 |